Imatinib (STI571)

目录号: GC10314纯度: >99.50%同义词: 伊马替尼; STI571; CGP-57148B
伊马替尼 (STI571) (STI571) 是一种口服生物可利用的酪氨酸激酶抑制剂,可选择性抑制 BCR/ABL、v-Abl、PDGFR 和 c-kit 激酶活性。伊马替尼 (STI571) (STI571) 通过在 ATP 结合位点附近结合而起作用,将其锁定在封闭或自我抑制的构象中,从而半竞争性地抑制蛋白质的酶活性。伊马替尼 (STI571) 也是 SARS-CoV 和 MERS-CoV 的抑制剂。

Imatinib (STI571)
Cas No.: 152459-95-5
规格价格库存数量操作
100mg¥504.00现货
1
10mM (in 1mL DMSO)¥357.00现货
1

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

Imatinib is an inhibitor of protein-tyrosine kinase with IC50 values of 0.1, 0.1 and 0.025μM, respectively against PDGF receptor, c-Kit and Abl [1].

The type 3 group of receptor tyrosine kinases includes PDGFR, CSF-1R, Flt-3, c-Kit and so on. PDGFRs are found in normal tissues, cells as well as some tumors. It is associated with several nonmalignant proliferative diseases. In vitro assays show that Imatinib can inhibit both PDGF-AA and PDGF-BB stimulated PDGF receptor phosphorylation. Imatinib is also found to inhibit the phosphorylation of c-Kit, another kinase which mediates the growth of a number of tumors. Imatinib inhibits the phosphorylation of these kinases without effecting the expression of them. Some other kinases of the type 3 group (such as Fms and Flt-3) can’t be inhibited by Imatinib, suggesting a selectivity of Imatinib. In addition, Imatinib is shown to significantly inhibit the Bcr-Abl tyrosine kinase both in cell-based assay and in vitro kinase assay. Moreover, as a downstream pathway of PDGF-mediated signals, MAP kinase activation can also be effected in rat A10 smooth muscle cells [1].

References:
[1] Elisabeth Buchdunger, Catherine L. Cioffi, Norman Law, David Stover, Sayuri Ohno-Jones, Brian J. Druker And Nicholas B. Lydon. Abl protein-tyrosine kinase inhibitor sti571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. The journal of pharmacology and experimental therapeutics. 2000, 295(1): 139-145.

实验参考方法 Experimental Reference Method

Kinase experiment [1]:

Binding assays

The kinase domains of Kdr, Flt-1, c-Met, and Tek were expressed in High Five cells using the Bac-to-Bac expression system. The proteins were then purified to near homogeneity by standard chromatographic techniques. Kinase inhibition was measured by detecting the decrease in phosphorylation of poly(Glu, Tyr) essential for the epidermal growth factor receptor. The in vitro kinase assays were carried out under optimized assay conditions (ATP concentration; Km). To determine whether Jak-2 was inhibited by STI571, 32Dp210 Bcr-Abl-expressing cells were serum starved for 8 h, and then stimulated for 10 min with 10% WEHI-3B-conditioned medium (IL-3 source). Nonidet P-40 lysates were prepared, and 500 mg of lysate was immunoprecipitated with either anti-Jak-2 antibodies (5 m l; Upstate Biotechnology), or anti-Abl antibodies (20 ml K12), overnight at 4°C. Immunoprecipitates were bound to protein G Sepharose for 1 h, washed three times with PBS, and then with kinase buffer (20 mM Tris, pH 7.5, 10 mM MgCl2 , 10 mM sodium vanadate, 1 mM dithiothreitol). Kinase assays were performed with or without 10 mM STI571, run on a 10% acryl-amide gel, and exposed on a phosphorimager.

Cell experiment [1]:

Cell lines

Swiss 3T3 cells, MO7e cells

Preparation method

The solubility of this compound in DMSO is >24.7mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

0-10 μM, 90 min, 37°C

Applications

Pretreatment of Swiss 3T3 cells with STI571 caused a dose-dependent inhibition of PDGF-AA-stimulated PDGF receptor phosphorylation with an IC50 value of ~0.1 μM. Treatment of MO7e cells with SCF in the presence of STI571 dose-dependently inhibited SCF-stimulated tyrosine phosphorylation with an IC50 value of ~0.1 μM. STI571 inhibited PDGF-BB-stimulated A10 cell proliferation with an IC50 value of 0.2 μM.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Elisabeth Buchdunger, Catherine L. Cioffi, Norman Law, David Stover, Sayuri Ohno-Jones, Brian J. Druker And Nicholas B. Lydon. Abl protein-tyrosine kinase inhibitor sti571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. The journal of pharmacology and experimental therapeutics. 2000, 295(1): 139-145.

产品文档 Product Documents

Purity:>99.50%

化学性质Chemical Properties

CAS 号
152459-95-5
同义词
伊马替尼; STI571; CGP-57148B
化学名
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
SMILES
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
分子式
C29H31N7O
分子量
493.6 g/mol
溶解性
≥ 24.68mg/mL in DMSO
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至 37°C,然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备 RT,或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol